These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24360237)

  • 1. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions.
    Dohi T; Iida O; Soga Y; Hirano K; Suzuki K; Takahara M; Uematsu M; Nanto S
    J Vasc Surg; 2014 Apr; 59(4):1009-1015.e1. PubMed ID: 24360237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
    J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis.
    Iida O; Soga Y; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M; Muramatsu T; Inoue N; Nanto S; Uematsu M
    J Endovasc Ther; 2011 Dec; 18(6):753-61. PubMed ID: 22149222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endovascular treatment for symptomatic stent failures in long-segment chronic total occlusion of femoropopliteal arteries.
    Yang X; Lu X; Li W; Huang Y; Huang X; Lu M; Jiang M
    J Vasc Surg; 2014 Aug; 60(2):362-8. PubMed ID: 24680242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Yokoi H; Uematsu M;
    J Vasc Surg; 2016 Dec; 64(6):1691-1695.e1. PubMed ID: 27575807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis.
    Kawamura Y; Ishii H; Aoyama T; Tanaka M; Takahashi H; Kumada Y; Toriyama T; Murohara T
    J Vasc Surg; 2009 Nov; 50(5):1057-62. PubMed ID: 19782527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Clinical Outcomes between Endovascular Therapy with Self-Expandable Nitinol Stent and Femoral-Popliteal Bypass for Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Lesions.
    Okuno S; Iida O; Iida T; Takahara M; Yamaoka T; Kitano I; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Mano T
    Ann Vasc Surg; 2019 May; 57():137-143. PubMed ID: 30500627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitinol stent implantation for femoropopliteal disease in patients on hemodialysis: results of the 3-year retrospective multicenter APOLLON study.
    Fujihara M; Higashimori A; Kato Y; Taniguchi H; Iwasaki Y; Amano T; Sumiyoshi A; Nishiya D; Yokoi Y
    Heart Vessels; 2016 Sep; 31(9):1476-83. PubMed ID: 26337619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
    Kamioka N; Soga Y; Kuramitsu S; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamaoka T; Suematsu N; Shintani Y; Miyashita Y; Takahashi H; Tsuchiya T; Shinozaki N; Okazaki S; Ando K
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):790-797. PubMed ID: 28722294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stent fractures after superficial femoral artery stenting: risk factors and impact on patency.
    Lin Y; Tang X; Fu W; Kovach R; George JC; Guo D
    J Endovasc Ther; 2015 Jun; 22(3):319-26. PubMed ID: 25862365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.